Insmed Inc (INSM) 13.41 $INSM
10.4% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Mon Apr 14, 9:30AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on March 26th, 2014 at $16.47. In approximately 3 weeks, Insmed has returned 10.42% as of today's recent price of $14.75.
Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
Marketwire - Mon Apr 07, 3:45PM CDT
Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13th Annual Needham & Co. Healthcare Conference taking place from April 8 - 9, 2014 at the Westin Grand Central Hotel in New York City.
Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities
eTeligis - Wed Apr 02, 5:05PM CDT
Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company focused on developing inhaled anti-infective treatments for patients battling lung diseases in orphan indications, announced today organizational changes and new leadership team appointments that will better align the organization with the Company's growth opportunities. These growth opportunities include the potential commercialization of Insmed's lead product candidate, ARIKAYCE, for two indications: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients withPseudomonas aeruginosainfections.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 31, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Insmed Incorporated saw its shares rise more than 7% in the session. - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:04AM CDT
Insmed Incorporated was a big mover last session, as the company saw its shares rise more than 7% on the day.
Insmed Down on Disappointing Arikayce Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:48PM CDT
Insmed shares skid over 13% after the company announced that Arikayce failed to meet the primary objective.
Insmed falls on mixed results
at Investor's Business Daily - Wed Mar 26, 5:50PM CDT
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint of a certain reduction in density of mycobacteria but met its secondary endpoint. "We are encouraged by the achievement of culture...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 26, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Movado and Facebook are big market movers
AP - Wed Mar 26, 3:41PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Insmed Incorporated Shares Sank
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 12:47PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insmed , a clinical-stage...
Insmed Falls On Mixed Results For Lung Drug
at Investor's Business Daily - Wed Mar 26, 11:18AM CDT
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint but met its secondary endpoint, sending the stock down 12% in heavy midday trading on the stock market today. The pre-specified...
Insmed's Mixed Lung Infection Data Will be Debated by Bulls and Bears
at The Street - Wed Mar 26, 9:03AM CDT
Did the Arikayce study in NTM lung infections succeed or not?
10.4% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Mon Apr 14, 9:30AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on March 26th, 2014 at $16.47. In approximately 3 weeks, Insmed has returned 10.42% as of today's recent price of $14.75.
Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
Marketwire - Mon Apr 07, 3:45PM CDT
Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13th Annual Needham & Co. Healthcare Conference taking place from April 8 - 9, 2014 at the Westin Grand Central Hotel in New York City.
Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities
eTeligis - Wed Apr 02, 5:05PM CDT
Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company focused on developing inhaled anti-infective treatments for patients battling lung diseases in orphan indications, announced today organizational changes and new leadership team appointments that will better align the organization with the Company's growth opportunities. These growth opportunities include the potential commercialization of Insmed's lead product candidate, ARIKAYCE, for two indications: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients withPseudomonas aeruginosainfections.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 31, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Insmed Incorporated saw its shares rise more than 7% in the session. - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:04AM CDT
Insmed Incorporated was a big mover last session, as the company saw its shares rise more than 7% on the day.
Insmed Down on Disappointing Arikayce Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:48PM CDT
Insmed shares skid over 13% after the company announced that Arikayce failed to meet the primary objective.
Insmed falls on mixed results
at Investor's Business Daily - Wed Mar 26, 5:50PM CDT
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint of a certain reduction in density of mycobacteria but met its secondary endpoint. "We are encouraged by the achievement of culture...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 26, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Movado and Facebook are big market movers
AP - Wed Mar 26, 3:41PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Insmed Incorporated Shares Sank
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 26, 12:47PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insmed , a clinical-stage...
Insmed Falls On Mixed Results For Lung Drug
at Investor's Business Daily - Wed Mar 26, 11:18AM CDT
Biotech Insmed (INSM) said a phase-two trial of its lung-infection drug Arikayce failed to meet its primary endpoint but met its secondary endpoint, sending the stock down 12% in heavy midday trading on the stock market today. The pre-specified...
Insmed's Mixed Lung Infection Data Will be Debated by Bulls and Bears
at The Street - Wed Mar 26, 9:03AM CDT
Did the Arikayce study in NTM lung infections succeed or not?
